Waldencast Exits Obagi Medical in $460M Sale to Bridgepoint
Event summary
- Waldencast completed the sale of Obagi Medical to Bridgepoint for up to $460M, subject to adjustments.
- Proceeds were used to repay Waldencast’s outstanding senior term loan facility.
- Key executives transitioned to lead Obagi Medical under Bridgepoint’s ownership.
- Felipe Dutra assumes principal executive and financial officer roles at Waldencast.
The big picture
Waldencast’s exit from Obagi Medical aligns with a broader trend of beauty conglomerates streamlining portfolios to focus on high-growth segments. The $460M transaction underscores Bridgepoint’s appetite for mid-market dermatology assets, while Waldencast aims to bolster Milk Makeup’s position in the clean prestige cosmetics space. The strategic pivot highlights the increasing importance of balance sheet agility in a fragmented beauty market.
What we're watching
- Focus Shift
- How Waldencast’s renewed focus on Milk Makeup will impact its growth trajectory.
- Execution Risk
- Whether the transition of key executives to Obagi Medical will disrupt operations at Waldencast.
- Strategic Allocation
- The pace at which Waldencast’s Board allocates remaining proceeds from the sale.
Related topics